Taysha Gene Therapies (TSHA) reported a widening net loss of $81.1 million for the nine months ended September 30, 2025, up from \(70.5 million in 2024, despite significant R&D investment (\)61.5 million YTD). Revenue declined year-over-year to \(4.3 million. The company's cash position is robust at **\)297.3 million**, bolstered by the May 2025 Equity Offering (net proceeds \(215.6 million), providing runway into 2028. The Accumulated Deficit grew to (\)683.4 million).
Pipeline and Strategic Updates: TSHA achieved a major regulatory milestone as the FDA granted **Breakthrough Therapy Desig
...